Project Grant R43HL145819

The National Heart, Lung, and Blood Institute awarded Perfusion Solutions Inc. $217,013 on August 1, 2026, to develop a bearingless, fail-safe pump for patients with single ventricle physiology following Fontan surgical palliation under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds Phase I research to design and develop a bearingless motor integrated into a centrifugal pump rotor, with the pump's stator incorporating the motor stator. The device is engineered to...

Percassist Inc. received a $663,129 Project Grant award from the National Heart Lung and Blood Institute of the Department of Health and Human Services. The award was made under the Cardiovascular Diseases Research program (CFDA 93.837), which supports heart and vascular research. The grant funds the development of a percutaneous ventricular assist device for chronic heart failure patients. Specifically, Percassist will design and test a balloon catheter implant that can be delivered minimally...

Federal Project Grant Award Summary Perfusion Solutions Inc. received a $320,838 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 5, 2025, with completion targeted for February 28, 2027. The award supports Phase I development of a fail-safe, high-output cavopulmonary assist pump designed for pediatric and congenital heart disease patients with single ventricle physiology...

The National Heart, Lung, and Blood Institute awarded Corvion, Inc. $2,999,968 on August 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a novel pediatric left ventricular assist device (P-LVAD) enabling children with end-stage heart failure to discharge home while awaiting heart transplantation or living long-term with the device. This is a Project Grant (SBIR Phase II). Corvion will engineer an implantable, ultra-low-power blood pump combining hydrodynamic...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Syncardia Systems, LLC $606,498 on September 1, 2026, under the Small Business Innovation Research (SBIR) Phase I program to develop and demonstrate feasibility of EMPEROR, a wearable, mechanically actuated total artificial heart enabling destination therapy for severe biventricular heart failure patients. EMPEROR replaces the pneumatic blood pump in the SynCardia TAH with a mechanically actuated pump that generates less noise,...

This National Science Foundation (NSF) Project Grant award under CFDA 47.041 (Engineering) supports the development of a new computational model to predict the complex interactions between ventricular assist devices (VADs) and the beating native heart. The goal is to create a "digital twin" of an experimental mock circulatory loop used for testing VAD safety and efficacy. This $195,291 award, effective August 1, 2024 through July 31, 2026, will result in a lumped parameter model that...

The National Heart, Lung, and Blood Institute awarded Bridgesource Medical, Corp. $320,727 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a right heart catheter device that uses pressure-volume loop analysis to identify which patients with tricuspid regurgitation will benefit from percutaneous valve repair procedures. The device addresses a critical clinical gap in patient selection for tricuspid valve interventions. Approximately 1.5 million...

This $7,836,599.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) will support the development of a novel centrifugal left ventricular assist device (LVAD) with wireless power transfer and anti-thrombotic coating technology. The prime awardee, Georgia Tech Research Corporation, will lead the research and development efforts, which include fabricating and characterizing slippery hydrophilic (SLIC) coatings to improve...

The National Heart, Lung, and Blood Institute awarded Aust Development, LLC a Phase I Small Business Innovation Research project grant of $626,604 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837). Aust Development will develop a novel 3D pre-shaped delivery catheter platform to enable precise identification and safe delivery of cardiac conduction system pacing leads. The delivery system will allow physicians to sequentially map the septal myocardium, fix...

The National Heart, Lung, and Blood Institute awarded $351,388 to Barron Associates, Inc. on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a noninvasive hemodynamic monitoring tool for heart failure patients. The project addresses the clinical gap in home and hospital monitoring of acute decompensated heart failure by creating a low-cost alternative to invasive right heart catheterization and costly implantable devices. The proposed solution...